Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT02017197
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT02017197 -
U1111-1155-4833
-
- Other papers using this trial's data
- Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT02017197. Randomized; triple masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2016-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Acronym
- WARFA
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Marevan®
- Intervention (Drug)
- generic warfarin #1
- Intervention (Drug)
- generic warfarin #2
- Lead sponsor
- Federal University of São Paulo
- Collaborator
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Record details
- Record id
cardio:ct-nct02017197- Content hash
54e66a27ad0186610548197e281feb280ea6681fa9e5febeb55cd1986532edc9